Sensitising cervix against cancer: Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study - Softcover
The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer.
"synopsis" may belong to another edition of this title.
About the Author:
Dr. Sanjoy Roy has been trained in Radiation Oncology from C.N.C.I and is attached with the department since 2006. His area of interest is Cervical cancer and Breast conservation. Currently he is involved in Conformal Therapy delivery technique in Cervical Cancer and also delivers training & guidance to DNB PG trainees.
"About this title" may belong to another edition of this title.
- PublisherLAP LAMBERT Academic Publishing
- Publication date2012
- ISBN 10 3659146692
- ISBN 13 9783659146695
- BindingPaperback
- Number of pages76
Buy New
Learn more about this copy
US$ 50.69
Shipping:
US$ 3.99
Within U.S.A.
Top Search Results from the AbeBooks Marketplace
Stock Image
Sensitising cervix against cancer: Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study
Published by
LAP LAMBERT Academic Publishing
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
Softcover
Quantity: > 20
Seller:
Rating
Book Description Condition: New. Seller Inventory # ABLIING23Mar3113020265995
Buy New
US$ 50.69
Convert currency
Stock Image
Sensitising cervix against cancer
Published by
LAP Lambert Academic Publishing
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
Softcover
Quantity: > 20
Seller:
Rating
Book Description Condition: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Seller Inventory # ria9783659146695_lsuk
Buy New
US$ 56.85
Convert currency
Stock Image
Sensitising cervix against cancer
Published by
LAP Lambert Academic Publishing 2012-06
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
PF
Quantity: 10
Seller:
Rating
Book Description PF. Condition: New. Seller Inventory # 6666-IUK-9783659146695
Buy New
US$ 53.26
Convert currency
Stock Image
Sensitising cervix against cancer Addition of gemcitabine to standard therapy in locally advanced cervical cancer A randomized comparative study
Published by
LAP LAMBERT Academic Publishing
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
PAP
Quantity: > 20
Seller:
Rating
Book Description PAP. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9783659146695
Buy New
US$ 73.16
Convert currency
Seller Image
Sensitising cervix against cancer
Published by
LAP Lambert Academic Publishing
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
Taschenbuch
Quantity: 2
Seller:
Rating
Book Description Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer. 76 pp. Englisch. Seller Inventory # 9783659146695
Buy New
US$ 54.74
Convert currency
Stock Image
Sensitising cervix against cancer Addition of gemcitabine to standard therapy in locally advanced cervical cancer A randomized comparative study
Published by
LAP LAMBERT Academic Publishing
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
PAP
Quantity: > 20
Seller:
Rating
Book Description PAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9783659146695
Buy New
US$ 59.53
Convert currency
Seller Image
Sensitising cervix against cancer : Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study
Published by
LAP Lambert Academic Publishing
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
Taschenbuch
Quantity: 2
Seller:
Rating
Book Description Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer. Seller Inventory # 9783659146695
Buy New
US$ 56.33
Convert currency
Seller Image
Sensitising cervix against cancer
Published by
LAP LAMBERT Academic Publishing
(2012)
ISBN 10: 3659146692
ISBN 13: 9783659146695
New
Kartoniert / Broschiert
Quantity: > 20
Seller:
Rating
Book Description Kartoniert / Broschiert. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Roy SanjoyDr. Sanjoy Roy has been trained in Radiation Oncology from C.N.C.I and is attached with the department since 2006. His area of interest is Cervical cancer and Breast conservation. Currently he is involved in Conformal Thera. Seller Inventory # 5134864
Buy New
US$ 46.55
Convert currency